{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:46:50Z","timestamp":1785732410438,"version":"3.56.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiovascular-kidney-metabolic (CKM) syndrome stage 4a encompasses elderly heart failure with preserved ejection fraction (HFpEF) patients with metabolic risk factors or chronic kidney disease (CKD). No existing HFpEF prediction tool has incorporated glycated haemoglobin A1c (HbA1c) alongside echocardiographic diastolic function parameters within a CKM-anchored architecture targeting quality-of-life (QoL) deterioration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop, internally validate, and temporally validate a least absolute shrinkage and selection operator (LASSO)-Cox nomogram for predicting the long-term composite endpoint of quality-of-life (QoL) deterioration and unplanned heart failure rehospitalisation in elderly CKM stage 4a HFpEF patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively enrolled 302 consecutive patients aged \u226560 years with HFpEF meeting CKM stage 4a criteria admitted between January 2020 and December 2023, and a separate temporal validation cohort (n = 102) admitted between January 2024 and June 2025. Eligible patients had confirmed HFpEF per 2021 European Society of Cardiology guidelines (symptomatic heart failure [New York Heart Association {NYHA} class II\u2013IV], left ventricular ejection fraction [LVEF] \u226550%, elevated N-terminal pro-B-type natriuretic peptide [NT-proBNP], and echocardiographic diastolic dysfunction) and fulfilled CKM stage 4a criteria (metabolic risk factors or CKD without dialysis dependency). The primary outcome was a composite of QoL deterioration (Minnesota Living with Heart Failure Questionnaire [MLHFQ] increase \u22655 points) and unplanned heart failure rehospitalisation. Feature selection used LASSO-Cox regression integrated with multiple imputation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The primary endpoint occurred in 116 patients (38.4%) over a median follow-up of 22.4 months. LASSO selected eight predictors: age, NYHA class, ln-NT-proBNP, estimated glomerular filtration rate (eGFR), uric acid, E\/e\u2032 ratio, left atrial volume index (LAVI), and HbA1c; LVEF was compressed to zero. The nomogram achieved C-indices of 0.812 (95% CI 0.770\u20130.854) in training, 0.790 (0.728\u20130.852) in internal validation, and 0.783 (0.718\u20130.848) in temporal validation. In the temporal validation cohort the integrated calibration index was 0.041 at 12 months. Decision curve analysis demonstrated net clinical benefit across threshold probabilities of 10%\u201385%. An exploratory CKM metabolic burden score stratified 24-month event rates at 21.6%, 41.3%, and 62.5%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An eight-variable nomogram integrating HbA1c with CKM-axis biomarkers and diastolic function parameters predicted the long-term composite of QoL deterioration and unplanned heart failure rehospitalisation in elderly CKM stage 4a HFpEF patients, with performance preserved in temporal validation. Prospective multicentre validation in geographically distinct populations is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1861971","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:26:31Z","timestamp":1785731191000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A clinical prediction model integrating cardiovascular-kidney-metabolic biomarkers for the composite outcome of quality-of-life deterioration and rehospitalization in elderly HFpEF patients"],"prefix":"10.3389","volume":"17","author":[{"given":"Chen","family":"He","sequence":"first","affiliation":[{"name":"Department of Ultrasound Medicine, Zhangjiakou First Hospital","place":["Zhangjiakou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Ultrasound Medicine, Zhangjiakou First Hospital","place":["Zhangjiakou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhangjiakou First Hospital","place":["Zhangjiakou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhangjiakou First Hospital","place":["Zhangjiakou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhangjiakou First Hospital","place":["Zhangjiakou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Li","sequence":"additional","affiliation":[{"name":"Administrative Office, Zhangjiakou First Hospital","place":["Zhangjiakou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.125.014031","article-title":"What exactly is cardiometabolic HFpEF: a phenotype or an endotype","volume":"19","author":"Packer","year":"2026","journal-title":"Circ Heart Fail"},{"key":"B6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12933-025-02774-w","article-title":"Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment","volume":"24","author":"Gorica","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000001113","article-title":"Obesity\/cardiometabolic phenotype of heart failure with preserved ejection fraction: mechanisms to recent trials","volume":"39","author":"Verma","year":"2024","journal-title":"Curr Opin Cardiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.0284","article-title":"Prognostic models for mortality and morbidity in heart failure with preserved ejection fraction","volume":"9","author":"McDowell","year":"2024","journal-title":"JAMA Cardiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1492717","article-title":"A web-based dynamic nomogram for predicting readmission in patients with heart failure with preserved ejection fraction","volume":"12","author":"Zhou","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs337","article-title":"Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies","volume":"34","author":"Pocock","year":"2013","journal-title":"Eur Heart J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0336809","article-title":"Predicting 30-day and 1-year mortality in heart failure with preserved ejection fraction (HFpEF)","volume":"20","author":"Shin","year":"2025","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC Expert Consensus Decision Pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.34133\/research.1339","article-title":"Spatiotemporal deep video-phenomapping decodes microvascular rarefaction in middle-aged and elder renovascular hypertension: a multi-modal study integrating spatial transcriptomics and mitochondrial pyroptosis","volume":"9","author":"Ju","year":"2026","journal-title":"Research (Wash D C)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m441","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy531","article-title":"Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF","volume":"39","author":"Shah","year":"2018","journal-title":"Eur Heart J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000066420.36123.35","article-title":"Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology","volume":"107","author":"Hare","year":"2003","journal-title":"Circulation"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag372","article-title":"ACADM-mediated fatty acid \u03b2-oxidation pathway in atherosclerosis and abdominal aortic aneurysm","author":"Zhang","year":"2026","journal-title":"Eur Heart J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.076075","article-title":"Low myocardial protein kinase G activity in heart failure with preserved ejection fraction","volume":"126","author":"van Heerebeek","year":"2012","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.108.193326","article-title":"Hypophosphorylation of the stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium","volume":"104","author":"Borb\u00e9ly","year":"2009","journal-title":"Circ Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.113.000539","article-title":"Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model","volume":"6","author":"Hamdani","year":"2013","journal-title":"Circ Heart Fail"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.15.1699","article-title":"The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the CHARM program","volume":"168","author":"Gerstein","year":"2008","journal-title":"Arch Intern Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s1056-8727(01)00227-6","article-title":"High and low hemoglobin glycation phenotypes in type 1 diabetes","volume":"16","author":"Hempe","year":"2002","journal-title":"J Diabetes Complications"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-154112","article-title":"Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c","volume":"112","author":"Cohen","year":"2008","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1581","article-title":"Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring","volume":"41","author":"Bergenstal","year":"2018","journal-title":"Diabetes Care"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction","volume":"17","author":"Borlaug","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.13643","article-title":"Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years","volume":"75","author":"Virdis","year":"2020","journal-title":"Hypertension"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000065637.10517.A0","article-title":"Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging","volume":"107","author":"Anker","year":"2003","journal-title":"Circulation"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.09.004","article-title":"Finerenone in patients with a recent worsening heart failure event: the FINEARTS-HF trial","volume":"85","author":"Desai","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2025.0025","article-title":"Finerenone for heart failure and risk estimated by the PREDICT-HFpEF model: a secondary analysis of FINEARTS-HF","volume":"10","author":"McDowell","year":"2025","journal-title":"JAMA Cardiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2025.11.027","article-title":"A novel deep learning system for STEMI prognostic prediction from multi-sequence cardiac magnetic resonance","volume":"70","author":"Chen","year":"2025","journal-title":"Sci Bull (Beijing)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1376","article-title":"PROBAST: a tool to assess the risk of bias and applicability of prediction model studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann Intern Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","article-title":"Calibration: the Achilles heel of predictive analytics","volume":"17","author":"Van Calster","year":"2019","journal-title":"BMC Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1861971\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:26:31Z","timestamp":1785731191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1861971\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":45,"alternative-id":["10.3389\/fendo.2026.1861971"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1861971","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1861971"}}